Genzyme which has struggled with manufacturing problems of its top products, said it would expand operations in Geel, Belgium, to support its drugs for Pompe disease. Genzyme, which is the target of an $18.5 billion takeover bid by France's Sanofi-Aventis, said it would build an additional manufacturing plant in Geel to support the long-term growth of its drugs, Myozyme and Lumizyme.
Carbon black manufacturer Orion Engineered Carbons plans to rationalize production lines in North and South America and EMEA.
BASF sells a majority stake in its coatings business to the investor Carlyle.
Merck to acquire the chromatography business of JSR Life Sciences, a leading provider of CDMO services, preclinical and translational clinical research, and bioprocessing solutions.
Building on the April 2025 announcement, Dow will take actions across its three operating segments to support European profitability, resulting in the closure of sites in Germany and the UK.
Novo Nordisk announced a global workforce reduction of approximately 9,000 positions to streamline operations and reinvest DKK 8 billion (€1 billion) in growth opportunities for diabetes and obesity treatments.
